<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00547248</url>
  </required_header>
  <id_info>
    <org_study_id>109509</org_study_id>
    <nct_id>NCT00547248</nct_id>
  </id_info>
  <brief_title>Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines</brief_title>
  <official_title>Booster Vaccination Course With the Pneumococcal Vaccine GSK 1024850A, DTPw-HBV/Hib and OPV or IPV in Children Who Completed the Primary Vaccination Course in Study 107007</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this observer blind study is to assess the safety in terms of fever &gt;39°C
      (rectal temperature) and the immunogenicity in terms of antibody response following a booster
      vaccination with pneumococcal vaccine GSK 1024850A at 12 to 18 months of age in children
      previously primed with the same vaccines including a pneumococcal conjugate vaccine
      co-administered with a diphtheria, tetanus, whole cell pertussis (DTPw)-combined vaccine and
      OPV or IPV vaccines. Subjects participating in this study should have received three doses of
      pneumococcal conjugate vaccine in the primary study.

      This protocol posting deals with objectives &amp; outcome measures of the booster phase. The
      objectives &amp; outcome measures of the primary phase are presented in a separate protocol
      posting (NCT number = NCT00344318)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 22, 2007</start_date>
  <completion_date type="Actual">October 7, 2008</completion_date>
  <primary_completion_date type="Actual">May 10, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Reporting Rectal Temperature Greater Than (&gt;) the Cut-off</measure>
    <time_frame>Within the 4-day (Days 0-3) period after booster vaccination</time_frame>
    <description>Fever was measured as rectal temperature. The cut-off was 39.0 degree Celsius (°C). Assessment of occurrences of fever &gt; 39.0 (°C) was performed after booster vaccination with Synflorix™ or Prevenar™ vaccines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>Within the 4-day (Days 0-3) period after booster vaccination</time_frame>
    <description>Solicited local symptoms assessed included pain, redness and swelling. &quot;Any&quot; was defined as incidence of the specified symptom regardless of intensity. Grade 3 pain was defined as crying when limb was moved/ spontaneously painful. Grade 3 swelling/ redness was defined as swelling/ redness greater than (&gt;) 30 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited General Symptoms</measure>
    <time_frame>Within the 4-day (Days 0-3) period after booster vaccination</time_frame>
    <description>Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature greater than or equal to (≥) 38.0°C), irritability, and loss of appetite.&quot;Any&quot; was defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) &gt;40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/ preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within the 31-day (Days 0-30) period after booster vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. &quot;Any&quot; was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events (SAEs)</measure>
    <time_frame>Throughout the active phase of the study (Month 0 to Month 1)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>The cut-off was 0.20 microgram per milliliter (μg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations to Protein D (Anti-PD)</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>Seropositivity status, defined as anti-PD antibody concentrations ≥100 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>Seropositivity status, defined as anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>Seropositivity status, defined as Opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A ≥ 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>The cut-off of the assay was 0.05 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>The cut-off for the assay was 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>The cut-of for the assay was 0.05 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A ≥ the Cut-off</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>The cut-off for the assay was 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Antibody Concentrations Against Protein D (Anti-PD) ≥ the Cut-off</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>The cut-off for the assay was 100 ELISA units per milliliter (EL.U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>Seroprotection status, defined as anti-diphtheria toxoid or anti-tetanus toxoid antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>Seroprotection status, defined as anti-PRP antibody concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Bordetella Pertussis (BPT) Antibody Concentrations</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>Seropositivity status, defined as anti-BPT antibody concentrations ≥ 15 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>Seroprotection status, defined as anti-HBs antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-polio Type 1, 2 and 3 Antibody Titers</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>Seroprotection status, defined as anti-polio type 1, anti-polio type 2 and anti-polio type 3 antibody titers ≥ 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-Bordetella Pertussis (BPT) With Concentrations ≥ the Cut-off</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>The cut-off for the assay was 15 EL.U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations ≥ the Cut-off</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>The cut-off for the assay was 0.1 milli-international units per milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>The cut-off for the assay was 0.15 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-PRP Antibody Concentration ≥ the Cut-off</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>The cut-off for the assay was 1.0 μg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>The cut-off for the assay was 10 mIU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Anti-polio Type 1, 2 and 3 (Anti-Polio 1, 2 and 3) Antibody Titers ≥ the Cut-off</measure>
    <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
    <description>The cut-off for the assay was 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Vaccine Response to Anti-Bordetella Pertussis (BPT)</measure>
    <time_frame>One month after booster vaccination (Month 1)</time_frame>
    <description>Vaccine response for anti-BPT, defined as the appearance of antibodies in subjects seronegative at pre-vaccination, or at least 2-fold increase of pre-vaccination antibody concentrations in those who were initially seropositive at pre-vaccination.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">756</enrollment>
  <condition>Infections, Streptococcal</condition>
  <arm_group>
    <arm_group_label>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix and Poliorix™ at 12-18 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Synflorix</intervention_name>
    <description>Intramuscular injection, 1 dose</description>
    <arm_group_label>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</arm_group_label>
    <arm_group_label>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</arm_group_label>
    <other_name>Pneumococcal conjugate vaccine GSK1024850A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tritanrix-HepB</intervention_name>
    <description>Intramuscular injection, 1 dose</description>
    <arm_group_label>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</arm_group_label>
    <arm_group_label>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</arm_group_label>
    <arm_group_label>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</arm_group_label>
    <arm_group_label>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</arm_group_label>
    <other_name>DTPw-HBV vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hiberix</intervention_name>
    <description>Reconstituted with Tritanrix-Hep B before injection</description>
    <arm_group_label>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</arm_group_label>
    <arm_group_label>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</arm_group_label>
    <arm_group_label>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</arm_group_label>
    <arm_group_label>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</arm_group_label>
    <other_name>Hib vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Polio Sabin</intervention_name>
    <description>Oral, 1 dose</description>
    <arm_group_label>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</arm_group_label>
    <arm_group_label>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</arm_group_label>
    <other_name>OPV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Poliorix</intervention_name>
    <description>Intramuscular injection, 1 dose</description>
    <arm_group_label>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</arm_group_label>
    <arm_group_label>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</arm_group_label>
    <other_name>IPV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar (Wyeth)</intervention_name>
    <description>Intramuscular injection, 1 dose</description>
    <arm_group_label>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</arm_group_label>
    <arm_group_label>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</arm_group_label>
    <other_name>Pneumococcal conjugate vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects for whom the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol.

          -  A male or female between, and including, 12-18 months of age at the time of the
             booster vaccination and who previously participated in study 107007 and received three
             doses of pneumococcal conjugate vaccine.

          -  Written informed consent obtained from the parent or guardian of the subject.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

        Exclusion Criteria:

          -  Concurrently participating in another clinical study, at any time during the study
             period (active phase and extended safety follow-up), in which the subject has been or
             will be exposed to an investigational or a non-investigational product (pharmaceutical
             product or device).

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccines within one month preceding the booster dose of study vaccines, or
             planned use during the entire study period

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within 6 months prior to the booster dose of study vaccines.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol,
             during the period starting one month before the booster dose of study vaccines and up
             to the follow-up visit.

          -  Administration of any pneumococcal, diphtheria, tetanus, pertussis, polio, hepatitis
             B, Haemophilus influenzae type b vaccine other than the study vaccines from study
             107007.

          -  History of, or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B,
             Haemophilus influenzae type b diseases.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccines.

          -  History of seizures (this criterion does not apply to subjects who have had a single,
             uncomplicated febrile convulsion in the past) or progressive neurological disease.

          -  Acute disease at the time of enrolment.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition based on
             medical history and physical examination

          -  A family history of congenital or hereditary immunodeficiency.

          -  Major congenital defects or serious chronic illness.

          -  Administration of immunoglobulins and/or any blood products within three months
             preceding the booster dose of study vaccines or planned administration during the
             active phase of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-394</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuchola</city>
        <zip>89-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50345</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>52-312</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Bermal N, Szenborn L, Edison A, Hernandez M, Pejcz J, Majda-Stanislawska E, Gatchalian S, Fanic A, Dieussaert I, Schuerman L. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines. Pediatr Infect Dis J. 2011 Jan;30(1):69-72. doi: 10.1097/INF.0b013e3181f2da06.</citation>
    <PMID>20980933</PMID>
  </reference>
  <reference>
    <citation>Bermal N et al. Primary and booster vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) co-administered with DTPw-HBV/Hib and polio vaccines. Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.</citation>
  </reference>
  <reference>
    <citation>Nancy B et al. Booster dose of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) administered to children in the Philippines: antibody responses and safety. Abstract presented at the 13th Asian Pacific Congress of Pediatrics (APCP). Shanghai, China, 14-18 October 2009.</citation>
  </reference>
  <reference>
    <citation>Schuerman L et al. Immune responses against cross-reactive pneumococcal serotypes 6A and 19A with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.</citation>
  </reference>
  <reference>
    <citation>Schuerman L et al. Immune responses to the non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) appear not influenced by co-administration with DTPw-combination vaccine. Abstract presented at the 7th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Tel Aviv, Israel, 14-18 March 2010.</citation>
  </reference>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>October 19, 2007</study_first_submitted>
  <study_first_submitted_qc>October 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2007</study_first_posted>
  <results_first_submitted>May 4, 2017</results_first_submitted>
  <results_first_submitted_qc>July 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2019</results_first_posted>
  <disposition_first_submitted>May 20, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>May 21, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 28, 2009</disposition_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Booster vaccination.</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Pneumococcal vaccine</keyword>
  <keyword>Safety</keyword>
  <keyword>Pneumococcal disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Streptococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>109509</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109509</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109509</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109509</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109509</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109509</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>109509</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>During the screening the following steps occurred: check for inclusion/exclusion criteria, contraindications/precautions, medical history of the subjects and signing informed consent forms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
          <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
        </group>
        <group group_id="P2">
          <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
          <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
        </group>
        <group group_id="P3">
          <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
          <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
        </group>
        <group group_id="P4">
          <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
          <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix and Poliorix at 12-18 months of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="280"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="285"/>
                <participants group_id="P4" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="280"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="275"/>
                <participants group_id="P4" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
          <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
        </group>
        <group group_id="B2">
          <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
          <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
        </group>
        <group group_id="B3">
          <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
          <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
        </group>
        <group group_id="B4">
          <title>Prevenar + Tritanrix - HepB/ Hiberix + Poliorix Group</title>
          <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="280"/>
            <count group_id="B2" value="93"/>
            <count group_id="B3" value="285"/>
            <count group_id="B4" value="98"/>
            <count group_id="B5" value="756"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.2" spread="0.66"/>
                    <measurement group_id="B2" value="16.2" spread="0.59"/>
                    <measurement group_id="B3" value="17.2" spread="0.84"/>
                    <measurement group_id="B4" value="17.2" spread="0.88"/>
                    <measurement group_id="B5" value="16.71" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gender Categorical</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="353"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Geographic ancestry</title>
              <category_list>
                <category>
                  <title>White - Caucasian / European heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="285"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="383"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - south east Asian heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Reporting Rectal Temperature Greater Than (&gt;) the Cut-off</title>
        <description>Fever was measured as rectal temperature. The cut-off was 39.0 degree Celsius (°C). Assessment of occurrences of fever &gt; 39.0 (°C) was performed after booster vaccination with Synflorix™ or Prevenar™ vaccines.</description>
        <time_frame>Within the 4-day (Days 0-3) period after booster vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects with the symptom sheets filled in. For the purpose of the analysis, subjects were pooled into two groups, according to the booster vaccine they have received (Synflorix™ or Prevenar™).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix Pooled Group</title>
            <description>Subjects primary vaccinated at 6-10-14 weeks of age, receiving a booster dose of Synflorix™ vaccine, either co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines in the Philippines or co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines in Poland, at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar Pooled Group</title>
            <description>Subjects primary vaccinated at 6-10-14 weeks of age, receiving a booster dose of the Prevenar™ vaccine, either co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines in the Philippines or co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines in Poland, at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Rectal Temperature Greater Than (&gt;) the Cut-off</title>
          <description>Fever was measured as rectal temperature. The cut-off was 39.0 degree Celsius (°C). Assessment of occurrences of fever &gt; 39.0 (°C) was performed after booster vaccination with Synflorix™ or Prevenar™ vaccines.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects with the symptom sheets filled in. For the purpose of the analysis, subjects were pooled into two groups, according to the booster vaccine they have received (Synflorix™ or Prevenar™).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="558"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was demonstrated if the difference in terms of incidence of post-immunization febrile reactions (rectal temperature &gt; 39.0°C) in Synflorix™ vaccine minus Prevenar™ did not exceed the pre-defined clinically acceptable threshold of 5% + half the incidence in Prevenar.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.82</ci_lower_limit>
            <ci_upper_limit>5.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed included pain, redness and swelling. &quot;Any&quot; was defined as incidence of the specified symptom regardless of intensity. Grade 3 pain was defined as crying when limb was moved/ spontaneously painful. Grade 3 swelling/ redness was defined as swelling/ redness greater than (&gt;) 30 millimeters (mm).</description>
        <time_frame>Within the 4-day (Days 0-3) period after booster vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects with the symptom sheet filled-in.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed included pain, redness and swelling. &quot;Any&quot; was defined as incidence of the specified symptom regardless of intensity. Grade 3 pain was defined as crying when limb was moved/ spontaneously painful. Grade 3 swelling/ redness was defined as swelling/ redness greater than (&gt;) 30 millimeters (mm).</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects with the symptom sheet filled-in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="278"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="248"/>
                    <measurement group_id="O4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="117"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="197"/>
                    <measurement group_id="O4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="158"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited General Symptoms</title>
        <description>Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature greater than or equal to (≥) 38.0°C), irritability, and loss of appetite.&quot;Any&quot; was defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) &gt;40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/ preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all.</description>
        <time_frame>Within the 4-day (Days 0-3) period after booster vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects with the symptom sheet filled-in.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited General Symptoms</title>
          <description>Solicited general symptoms assessed include drowsiness, fever (defined as rectal temperature greater than or equal to (≥) 38.0°C), irritability, and loss of appetite.&quot;Any&quot; was defined as incidence of the specified symptom regardless of intensity or relationship to study vaccination. Grade 3 drowsiness was defined as drowsiness which prevented normal everyday activities. Grade 3 fever was defined as fever (rectal temperature) &gt;40.0 degree Celsius (°C). Grade 3 irritability was defined as crying that could not be comforted/ preventing normal activity. Grade 3 loss of appetite was defined as the subject not eating at all.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects with the symptom sheet filled-in.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="278"/>
                <count group_id="O4" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="190"/>
                    <measurement group_id="O4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="215"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="243"/>
                    <measurement group_id="O4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="184"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. &quot;Any&quot; was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
        <time_frame>Within the 31-day (Days 0-30) period after booster vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. &quot;Any&quot; was defined an incidence of an unsolicited AE regardless of intensity or relationship to study vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="106"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.</description>
        <time_frame>Throughout the active phase of the study (Month 0 to Month 1)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/ incapacity.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="285"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off</title>
        <description>The cut-off was 0.20 microgram per milliliter (μg/mL).</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off</title>
          <description>The cut-off was 0.20 microgram per milliliter (μg/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="64"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-1, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="124"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="122"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="118"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="116"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="111"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="121"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="123"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="89"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="123"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations</title>
        <description>Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations</title>
          <description>Seropositivity status, defined as anti-pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="0.29" upper_limit="0.42"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                    <measurement group_id="O3" value="0.19" lower_limit="0.16" upper_limit="0.22"/>
                    <measurement group_id="O4" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-1, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="9.22" upper_limit="12.66"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                    <measurement group_id="O3" value="2.14" lower_limit="1.8" upper_limit="2.55"/>
                    <measurement group_id="O4" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" lower_limit="0.45" upper_limit="0.67"/>
                    <measurement group_id="O2" value="0.34" lower_limit="0.25" upper_limit="0.45"/>
                    <measurement group_id="O3" value="0.27" lower_limit="0.22" upper_limit="0.33"/>
                    <measurement group_id="O4" value="0.24" lower_limit="0.19" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.16" lower_limit="11.43" upper_limit="15.14"/>
                    <measurement group_id="O2" value="11.84" lower_limit="8.74" upper_limit="16.04"/>
                    <measurement group_id="O3" value="4.21" lower_limit="3.61" upper_limit="4.91"/>
                    <measurement group_id="O4" value="6.86" lower_limit="5.39" upper_limit="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" lower_limit="0.47" upper_limit="0.64"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.04" upper_limit="0.09"/>
                    <measurement group_id="O3" value="0.4" lower_limit="0.34" upper_limit="0.47"/>
                    <measurement group_id="O4" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.59" lower_limit="12.53" upper_limit="16.99"/>
                    <measurement group_id="O2" value="0.09" lower_limit="0.06" upper_limit="0.13"/>
                    <measurement group_id="O3" value="2.54" lower_limit="2.11" upper_limit="3.06"/>
                    <measurement group_id="O4" value="0.05" lower_limit="0.04" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.54" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.38" lower_limit="0.22" upper_limit="0.65"/>
                    <measurement group_id="O3" value="0.34" lower_limit="0.28" upper_limit="0.41"/>
                    <measurement group_id="O4" value="0.34" lower_limit="0.2" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.02" lower_limit="5.83" upper_limit="8.45"/>
                    <measurement group_id="O2" value="9.08" lower_limit="6.5" upper_limit="12.7"/>
                    <measurement group_id="O3" value="2.31" lower_limit="1.93" upper_limit="2.75"/>
                    <measurement group_id="O4" value="6.28" lower_limit="4.18" upper_limit="9.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.77" upper_limit="1.04"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.03" upper_limit="0.07"/>
                    <measurement group_id="O3" value="0.58" lower_limit="0.51" upper_limit="0.67"/>
                    <measurement group_id="O4" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.52" lower_limit="11.09" upper_limit="14.13"/>
                    <measurement group_id="O2" value="0.06" lower_limit="0.04" upper_limit="0.1"/>
                    <measurement group_id="O3" value="4.14" lower_limit="3.61" upper_limit="4.74"/>
                    <measurement group_id="O4" value="0.03" lower_limit="0.03" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" lower_limit="0.98" upper_limit="1.37"/>
                    <measurement group_id="O2" value="0.77" lower_limit="0.59" upper_limit="0.99"/>
                    <measurement group_id="O3" value="0.59" lower_limit="0.5" upper_limit="0.7"/>
                    <measurement group_id="O4" value="0.58" lower_limit="0.47" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.42" lower_limit="12.44" upper_limit="16.7"/>
                    <measurement group_id="O2" value="20.31" lower_limit="15.44" upper_limit="26.71"/>
                    <measurement group_id="O3" value="4.63" lower_limit="4" upper_limit="5.36"/>
                    <measurement group_id="O4" value="13.6" lower_limit="11.12" upper_limit="16.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="1.07" upper_limit="1.63"/>
                    <measurement group_id="O2" value="1.83" lower_limit="1.26" upper_limit="2.66"/>
                    <measurement group_id="O3" value="0.84" lower_limit="0.66" upper_limit="1.07"/>
                    <measurement group_id="O4" value="1.04" lower_limit="0.75" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.07" lower_limit="14.12" upper_limit="20.64"/>
                    <measurement group_id="O2" value="27.42" lower_limit="20.96" upper_limit="35.86"/>
                    <measurement group_id="O3" value="5.93" lower_limit="4.97" upper_limit="7.09"/>
                    <measurement group_id="O4" value="15.51" lower_limit="12.14" upper_limit="19.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" lower_limit="1.2" upper_limit="1.71"/>
                    <measurement group_id="O2" value="0.42" lower_limit="0.32" upper_limit="0.55"/>
                    <measurement group_id="O3" value="0.63" lower_limit="0.52" upper_limit="0.77"/>
                    <measurement group_id="O4" value="0.4" lower_limit="0.3" upper_limit="053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.59" lower_limit="34.04" upper_limit="46.05"/>
                    <measurement group_id="O2" value="12.07" lower_limit="9.23" upper_limit="15.79"/>
                    <measurement group_id="O3" value="10.49" lower_limit="8.81" upper_limit="12.49"/>
                    <measurement group_id="O4" value="9.92" lower_limit="7.74" upper_limit="12.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="1.08" upper_limit="1.64"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.1" upper_limit="0.26"/>
                    <measurement group_id="O3" value="0.99" lower_limit="0.81" upper_limit="1.22"/>
                    <measurement group_id="O4" value="0.35" lower_limit="0.2" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.25" lower_limit="18.07" upper_limit="24.98"/>
                    <measurement group_id="O2" value="6.61" lower_limit="4.9" upper_limit="8.92"/>
                    <measurement group_id="O3" value="12.23" lower_limit="9.89" upper_limit="15.13"/>
                    <measurement group_id="O4" value="6.01" lower_limit="4.75" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.76" upper_limit="1.16"/>
                    <measurement group_id="O2" value="0.41" lower_limit="0.26" upper_limit="0.64"/>
                    <measurement group_id="O3" value="0.33" lower_limit="0.27" upper_limit="0.4"/>
                    <measurement group_id="O4" value="0.62" lower_limit="0.43" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.47" lower_limit="11.38" upper_limit="15.94"/>
                    <measurement group_id="O2" value="14.78" lower_limit="9.45" upper_limit="23.11"/>
                    <measurement group_id="O3" value="3.16" lower_limit="2.61" upper_limit="3.83"/>
                    <measurement group_id="O4" value="10.77" lower_limit="7.19" upper_limit="16.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F</title>
        <description>Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ 8.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F</title>
          <description>Seropositivity status, defined as Opsonophagocytic activity against pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ 8.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPA Anti-1, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="122"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="10.2" upper_limit="16.9"/>
                    <measurement group_id="O2" value="4.6" lower_limit="3.9" upper_limit="5.4"/>
                    <measurement group_id="O3" value="8.5" lower_limit="7" upper_limit="10.5"/>
                    <measurement group_id="O4" value="4.7" lower_limit="3.8" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-1, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="120"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1571.6" lower_limit="1210.7" upper_limit="2040"/>
                    <measurement group_id="O2" value="4.9" lower_limit="4.1" upper_limit="5.8"/>
                    <measurement group_id="O3" value="161.4" lower_limit="120.7" upper_limit="215.9"/>
                    <measurement group_id="O4" value="5.4" lower_limit="4" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-4, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="114"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="27.6" upper_limit="59.2"/>
                    <measurement group_id="O2" value="18.5" lower_limit="10" upper_limit="34.2"/>
                    <measurement group_id="O3" value="12.5" lower_limit="8.9" upper_limit="17.4"/>
                    <measurement group_id="O4" value="12.4" lower_limit="6.7" upper_limit="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-4, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5035.8" lower_limit="4214" upper_limit="6017.8"/>
                    <measurement group_id="O2" value="4783.5" lower_limit="3432" upper_limit="6667.2"/>
                    <measurement group_id="O3" value="2498.7" lower_limit="2103.3" upper_limit="2968.4"/>
                    <measurement group_id="O4" value="4812.5" lower_limit="3167.8" upper_limit="7311.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-5, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" lower_limit="16" upper_limit="24.7"/>
                    <measurement group_id="O2" value="4.2" lower_limit="3.8" upper_limit="4.6"/>
                    <measurement group_id="O3" value="10.9" lower_limit="8.8" upper_limit="13.6"/>
                    <measurement group_id="O4" value="4.5" lower_limit="3.7" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-5, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="117"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1135.8" lower_limit="928.5" upper_limit="1389.6"/>
                    <measurement group_id="O2" value="4.9" lower_limit="3.9" upper_limit="6"/>
                    <measurement group_id="O3" value="149.1" lower_limit="115.4" upper_limit="192.5"/>
                    <measurement group_id="O4" value="4.3" lower_limit="3.8" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-6B, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="124"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="61.5" upper_limit="155.5"/>
                    <measurement group_id="O2" value="56.6" lower_limit="21.3" upper_limit="150.1"/>
                    <measurement group_id="O3" value="9.9" lower_limit="7.2" upper_limit="13.5"/>
                    <measurement group_id="O4" value="23.3" lower_limit="9.1" upper_limit="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-6B, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="120"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2896.8" lower_limit="2247.5" upper_limit="3733.8"/>
                    <measurement group_id="O2" value="9302.7" lower_limit="7187.3" upper_limit="12040.8"/>
                    <measurement group_id="O3" value="405.3" lower_limit="267.4" upper_limit="614.3"/>
                    <measurement group_id="O4" value="3547.1" lower_limit="1500.7" upper_limit="8384.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-7F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="116"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2278.4" lower_limit="1803.1" upper_limit="2879"/>
                    <measurement group_id="O2" value="378.8" lower_limit="136.9" upper_limit="1048"/>
                    <measurement group_id="O3" value="796.3" lower_limit="582.2" upper_limit="1089.1"/>
                    <measurement group_id="O4" value="63.6" lower_limit="21.3" upper_limit="190.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-7F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="122"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12484" lower_limit="10750.7" upper_limit="14496.8"/>
                    <measurement group_id="O2" value="1407.7" lower_limit="694.6" upper_limit="2852.9"/>
                    <measurement group_id="O3" value="6436.1" lower_limit="5507.6" upper_limit="7521"/>
                    <measurement group_id="O4" value="90.6" lower_limit="25.2" upper_limit="325.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-9V, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="122"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="788" lower_limit="655.1" upper_limit="947.8"/>
                    <measurement group_id="O2" value="666.8" lower_limit="482.1" upper_limit="922.2"/>
                    <measurement group_id="O3" value="380.2" lower_limit="313.1" upper_limit="461.7"/>
                    <measurement group_id="O4" value="247.5" lower_limit="164.9" upper_limit="371.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-9V, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4842" lower_limit="4122.7" upper_limit="5686.9"/>
                    <measurement group_id="O2" value="7387.8" lower_limit="5429.2" upper_limit="10052.9"/>
                    <measurement group_id="O3" value="3499.9" lower_limit="2950.8" upper_limit="4151.3"/>
                    <measurement group_id="O4" value="6881.4" lower_limit="4883.6" upper_limit="9696.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-14, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="106"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298.4" lower_limit="220.1" upper_limit="404.7"/>
                    <measurement group_id="O2" value="337.2" lower_limit="207" upper_limit="549.2"/>
                    <measurement group_id="O3" value="179.6" lower_limit="127.4" upper_limit="253.2"/>
                    <measurement group_id="O4" value="236.6" lower_limit="132.6" upper_limit="422.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-14, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="120"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3579.7" lower_limit="2966.3" upper_limit="4319.9"/>
                    <measurement group_id="O2" value="4097.3" lower_limit="3019.2" upper_limit="5560.2"/>
                    <measurement group_id="O3" value="1961.3" lower_limit="1630" upper_limit="2359.8"/>
                    <measurement group_id="O4" value="2939.5" lower_limit="2022.3" upper_limit="4272.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-18C, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" lower_limit="15.2" upper_limit="25.9"/>
                    <measurement group_id="O2" value="4.5" lower_limit="3.9" upper_limit="5.2"/>
                    <measurement group_id="O3" value="7.8" lower_limit="6.5" upper_limit="9.4"/>
                    <measurement group_id="O4" value="4.5" lower_limit="4" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-18C, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="115"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2417.2" lower_limit="1989.9" upper_limit="2936.2"/>
                    <measurement group_id="O2" value="966.5" lower_limit="607.1" upper_limit="1538.6"/>
                    <measurement group_id="O3" value="694" lower_limit="532.9" upper_limit="903.7"/>
                    <measurement group_id="O4" value="612.1" lower_limit="338.4" upper_limit="1107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-19F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="45.2" upper_limit="76"/>
                    <measurement group_id="O2" value="7.3" lower_limit="4.5" upper_limit="11.8"/>
                    <measurement group_id="O3" value="33.3" lower_limit="25.7" upper_limit="43.2"/>
                    <measurement group_id="O4" value="11.1" lower_limit="6" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-19F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="122"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2016" lower_limit="1609" upper_limit="2526"/>
                    <measurement group_id="O2" value="473.2" lower_limit="263.5" upper_limit="849.9"/>
                    <measurement group_id="O3" value="1059.8" lower_limit="808.2" upper_limit="1389.7"/>
                    <measurement group_id="O4" value="471" lower_limit="270" upper_limit="821.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-23F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="948.9" lower_limit="688.4" upper_limit="1308.2"/>
                    <measurement group_id="O2" value="661.9" lower_limit="312.5" upper_limit="1402"/>
                    <measurement group_id="O3" value="301.8" lower_limit="198.4" upper_limit="459"/>
                    <measurement group_id="O4" value="790.6" lower_limit="326.8" upper_limit="1912.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-23F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7456.2" lower_limit="6301.9" upper_limit="8822"/>
                    <measurement group_id="O2" value="23177.9" lower_limit="13235.9" upper_limit="40587.7"/>
                    <measurement group_id="O3" value="3427.3" lower_limit="2727.7" upper_limit="4306.3"/>
                    <measurement group_id="O4" value="19943.3" lower_limit="13473.1" upper_limit="29520.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations to Protein D (Anti-PD)</title>
        <description>Seropositivity status, defined as anti-PD antibody concentrations ≥100 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations to Protein D (Anti-PD)</title>
          <description>Seropositivity status, defined as anti-PD antibody concentrations ≥100 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="128"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PD, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="573.1" lower_limit="495.7" upper_limit="662.6"/>
                    <measurement group_id="O2" value="136.8" lower_limit="102" upper_limit="183.3"/>
                    <measurement group_id="O3" value="526.8" lower_limit="427.4" upper_limit="649.3"/>
                    <measurement group_id="O4" value="73.8" lower_limit="58.4" upper_limit="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PD, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4973.9" lower_limit="4280.2" upper_limit="5780"/>
                    <measurement group_id="O2" value="124.1" lower_limit="92.8" upper_limit="166"/>
                    <measurement group_id="O3" value="2769.6" lower_limit="2308.5" upper_limit="3322.7"/>
                    <measurement group_id="O4" value="91.6" lower_limit="72" upper_limit="116.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A</title>
        <description>Seropositivity status, defined as anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against Pneumococcal Cross-reactive Serotypes 6A and 19A</title>
          <description>Seropositivity status, defined as anti-pneumococcal cross-reactive serotypes 6A and 19A antibody concentrations ≥ 0.05 microgram per milliliter (μg/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-6A, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" lower_limit="0.36" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.24" lower_limit="0.14" upper_limit="0.4"/>
                    <measurement group_id="O3" value="0.12" lower_limit="0.1" upper_limit="0.14"/>
                    <measurement group_id="O4" value="0.13" lower_limit="0.08" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" lower_limit="3.09" upper_limit="5.36"/>
                    <measurement group_id="O2" value="4.57" lower_limit="2.92" upper_limit="7.17"/>
                    <measurement group_id="O3" value="0.84" lower_limit="0.65" upper_limit="1.08"/>
                    <measurement group_id="O4" value="2.54" lower_limit="1.65" upper_limit="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.19" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.08" lower_limit="0.05" upper_limit="0.12"/>
                    <measurement group_id="O3" value="0.16" lower_limit="0.12" upper_limit="0.2"/>
                    <measurement group_id="O4" value="0.06" lower_limit="0.04" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" lower_limit="2.46" upper_limit="4.21"/>
                    <measurement group_id="O2" value="0.58" lower_limit="0.37" upper_limit="0.91"/>
                    <measurement group_id="O3" value="1.75" lower_limit="1.27" upper_limit="2.43"/>
                    <measurement group_id="O4" value="0.38" lower_limit="0.25" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A</title>
        <description>Seropositivity status, defined as Opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A ≥ 8.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A</title>
          <description>Seropositivity status, defined as Opsonophagocytic activity against pneumococcal cross-reactive serotypes 6A and 19A ≥ 8.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available, This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="123"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPA Anti-6A, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.6" lower_limit="73.6" upper_limit="175.4"/>
                    <measurement group_id="O2" value="191.4" lower_limit="89.7" upper_limit="408.2"/>
                    <measurement group_id="O3" value="46.8" lower_limit="30.8" upper_limit="71.1"/>
                    <measurement group_id="O4" value="42.2" lower_limit="19.3" upper_limit="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-6A, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="882.8" lower_limit="665.9" upper_limit="1170.3"/>
                    <measurement group_id="O2" value="2563.8" lower_limit="1689.9" upper_limit="3889.4"/>
                    <measurement group_id="O3" value="369.7" lower_limit="258.5" upper_limit="528.8"/>
                    <measurement group_id="O4" value="1394.5" lower_limit="827.9" upper_limit="2348.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-19A, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="123"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.5" upper_limit="6.3"/>
                    <measurement group_id="O2" value="5.1" lower_limit="3.6" upper_limit="7.3"/>
                    <measurement group_id="O3" value="5.3" lower_limit="4.5" upper_limit="6.2"/>
                    <measurement group_id="O4" value="4.4" lower_limit="3.6" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-19A, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="115"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" lower_limit="58.9" upper_limit="135.4"/>
                    <measurement group_id="O2" value="8.7" lower_limit="5.4" upper_limit="14.2"/>
                    <measurement group_id="O3" value="70.7" lower_limit="45.3" upper_limit="110.4"/>
                    <measurement group_id="O4" value="20.3" lower_limit="8.8" upper_limit="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off</title>
        <description>The cut-off of the assay was 0.05 μg/mL.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F Antibody Concentrations ≥ the Cut-off</title>
          <description>The cut-off of the assay was 0.05 μg/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-1, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="122"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-1, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="126"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-4, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-5, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="129"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="127"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6B, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="124"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-7F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-9V, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-14, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="129"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-18C, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="129"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="124"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-23F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="124"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off</title>
        <description>The cut-off for the assay was 8.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Opsonophagocytic Activity (OPA) Titers Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F ≥ the Cut-off</title>
          <description>The cut-off for the assay was 8.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPA Anti-1, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="122"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-1, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="120"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-4, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="127"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="114"/>
                    <count group_id="O4" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-4, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="119"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-5, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="119"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-5, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="117"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-6B, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="124"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-6B, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="120"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="106"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-7F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="116"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-7F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="122"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="122"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-9V, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="122"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="121"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-9V, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="121"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-14, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="106"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-14, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="120"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="120"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-18C, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="129"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-18C, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="115"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-19F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-19F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="122"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="118"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-23F, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="118"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-23F, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="121"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="120"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off</title>
        <description>The cut-of for the assay was 0.05 μg/mL.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Concentrations of Antibodies Against Cross-reactive Pneumococcal Serotypes 6A and 19A ≥ the Cut-off</title>
          <description>The cut-of for the assay was 0.05 μg/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="130"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-6A, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-6A, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="130"/>
                    <count group_id="O4" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-19A, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="136"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="119"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A ≥ the Cut-off</title>
        <description>The cut-off for the assay was 8.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Opsonophagocytic Activity (OPA) Against Pneumococcal Cross-reactive Serotypes 6A and 19A ≥ the Cut-off</title>
          <description>The cut-off for the assay was 8.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="123"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>OPA Anti-6A, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="117"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-6A, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-19A, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="134"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="123"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OPA Anti-19A, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="133"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="115"/>
                    <count group_id="O4" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Antibody Concentrations Against Protein D (Anti-PD) ≥ the Cut-off</title>
        <description>The cut-off for the assay was 100 ELISA units per milliliter (EL.U/mL).</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Antibody Concentrations Against Protein D (Anti-PD) ≥ the Cut-off</title>
          <description>The cut-off for the assay was 100 ELISA units per milliliter (EL.U/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="128"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PD, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="132"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="128"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="117"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PD, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="135"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="125"/>
                    <count group_id="O4" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations</title>
        <description>Seroprotection status, defined as anti-diphtheria toxoid or anti-tetanus toxoid antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations</title>
          <description>Seroprotection status, defined as anti-diphtheria toxoid or anti-tetanus toxoid antibody concentrations ≥ 0.1 international units per milliliter (IU/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-DT, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.258" lower_limit="0.209" upper_limit="0.319"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.118" upper_limit="0.243"/>
                    <measurement group_id="O3" value="0.188" lower_limit="0.153" upper_limit="0.231"/>
                    <measurement group_id="O4" value="0.126" lower_limit="0.088" upper_limit="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-DT, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.829" lower_limit="6.339" upper_limit="9.671"/>
                    <measurement group_id="O2" value="4.768" lower_limit="3.699" upper_limit="6.145"/>
                    <measurement group_id="O3" value="8.463" lower_limit="7.11" upper_limit="10.074"/>
                    <measurement group_id="O4" value="4.876" lower_limit="3.503" upper_limit="6.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TT, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.735" lower_limit="0.629" upper_limit="0.858"/>
                    <measurement group_id="O2" value="0.455" lower_limit="0.314" upper_limit="0.66"/>
                    <measurement group_id="O3" value="0.568" lower_limit="0.432" upper_limit="0.748"/>
                    <measurement group_id="O4" value="0.525" lower_limit="0.29" upper_limit="0.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TT, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.979" lower_limit="18.359" upper_limit="23.972"/>
                    <measurement group_id="O2" value="9.703" lower_limit="8.173" upper_limit="11.518"/>
                    <measurement group_id="O3" value="12.171" lower_limit="9.772" upper_limit="15.16"/>
                    <measurement group_id="O4" value="6.719" lower_limit="4.598" upper_limit="9.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations</title>
        <description>Seroprotection status, defined as anti-PRP antibody concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix™ Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Antibody Concentrations</title>
          <description>Seroprotection status, defined as anti-PRP antibody concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PRP, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.335" lower_limit="3.578" upper_limit="7.953"/>
                    <measurement group_id="O2" value="6.433" lower_limit="2.93" upper_limit="14.124"/>
                    <measurement group_id="O3" value="1.03" lower_limit="0.745" upper_limit="1.423"/>
                    <measurement group_id="O4" value="0.894" lower_limit="0.57" upper_limit="1.401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.004" lower_limit="79.937" upper_limit="140.572"/>
                    <measurement group_id="O2" value="89.376" lower_limit="55.131" upper_limit="144.891"/>
                    <measurement group_id="O3" value="53.386" lower_limit="34.817" upper_limit="81.858"/>
                    <measurement group_id="O4" value="33.656" lower_limit="19.464" upper_limit="58.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-Bordetella Pertussis (BPT) Antibody Concentrations</title>
        <description>Seropositivity status, defined as anti-BPT antibody concentrations ≥ 15 EL.U/mL.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-Bordetella Pertussis (BPT) Antibody Concentrations</title>
          <description>Seropositivity status, defined as anti-BPT antibody concentrations ≥ 15 EL.U/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-BPT, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.88" lower_limit="10.86" upper_limit="15.28"/>
                    <measurement group_id="O2" value="12.46" lower_limit="9.32" upper_limit="16.65"/>
                    <measurement group_id="O3" value="9.54" lower_limit="8.34" upper_limit="10.91"/>
                    <measurement group_id="O4" value="10" lower_limit="8.21" upper_limit="12.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-BPT, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.51" lower_limit="123.26" upper_limit="157.89"/>
                    <measurement group_id="O2" value="133.45" lower_limit="110.33" upper_limit="161.4"/>
                    <measurement group_id="O3" value="121.73" lower_limit="103.16" upper_limit="143.64"/>
                    <measurement group_id="O4" value="121.76" lower_limit="91.81" upper_limit="161.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations</title>
        <description>Seroprotection status, defined as anti-HBs antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL).</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations</title>
          <description>Seroprotection status, defined as anti-HBs antibody concentrations ≥ 10 milli international units per milliliter (mIU/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HBs, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="21.1" upper_limit="42.8"/>
                    <measurement group_id="O2" value="23.4" lower_limit="11.5" upper_limit="47.7"/>
                    <measurement group_id="O3" value="97.9" lower_limit="77" upper_limit="124.5"/>
                    <measurement group_id="O4" value="113" lower_limit="55.1" upper_limit="231.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HBs, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1220.5" lower_limit="790.6" upper_limit="1884"/>
                    <measurement group_id="O2" value="1098.1" lower_limit="358.4" upper_limit="3364.9"/>
                    <measurement group_id="O3" value="4428.7" lower_limit="2980.3" upper_limit="6581"/>
                    <measurement group_id="O4" value="3188.6" lower_limit="1171.7" upper_limit="8677.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-polio Type 1, 2 and 3 Antibody Titers</title>
        <description>Seroprotection status, defined as anti-polio type 1, anti-polio type 2 and anti-polio type 3 antibody titers ≥ 8.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix™ Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-polio Type 1, 2 and 3 Antibody Titers</title>
          <description>Seroprotection status, defined as anti-polio type 1, anti-polio type 2 and anti-polio type 3 antibody titers ≥ 8.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Polio 1, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329.1" lower_limit="214.9" upper_limit="504.1"/>
                    <measurement group_id="O2" value="269" lower_limit="114.8" upper_limit="630.3"/>
                    <measurement group_id="O3" value="46.5" lower_limit="33.6" upper_limit="64.4"/>
                    <measurement group_id="O4" value="51.1" lower_limit="28.4" upper_limit="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="854.6" lower_limit="573.5" upper_limit="1273.5"/>
                    <measurement group_id="O2" value="426.9" lower_limit="166.2" upper_limit="1096.7"/>
                    <measurement group_id="O3" value="932.5" lower_limit="770.5" upper_limit="1128.6"/>
                    <measurement group_id="O4" value="727.3" lower_limit="512.9" upper_limit="1059.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.6" lower_limit="171.8" upper_limit="288.3"/>
                    <measurement group_id="O2" value="210.4" lower_limit="115.4" upper_limit="383.6"/>
                    <measurement group_id="O3" value="50.2" lower_limit="36.9" upper_limit="68.2"/>
                    <measurement group_id="O4" value="60.8" lower_limit="33.4" upper_limit="110.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="716.9" lower_limit="487.6" upper_limit="1054.1"/>
                    <measurement group_id="O2" value="689.1" lower_limit="304.8" upper_limit="1557.9"/>
                    <measurement group_id="O3" value="1195.7" lower_limit="977.8" upper_limit="1462.2"/>
                    <measurement group_id="O4" value="1206.6" lower_limit="737" upper_limit="1975.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.2" lower_limit="73.9" upper_limit="141.5"/>
                    <measurement group_id="O2" value="38.4" lower_limit="20.3" upper_limit="72.9"/>
                    <measurement group_id="O3" value="51.8" lower_limit="37.4" upper_limit="71.7"/>
                    <measurement group_id="O4" value="71.1" lower_limit="36.2" upper_limit="139.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232.7" lower_limit="159.6" upper_limit="339.4"/>
                    <measurement group_id="O2" value="190.4" lower_limit="78.2" upper_limit="463.6"/>
                    <measurement group_id="O3" value="1464.2" lower_limit="1128" upper_limit="1900.6"/>
                    <measurement group_id="O4" value="1346.2" lower_limit="857.6" upper_limit="2113.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-Bordetella Pertussis (BPT) With Concentrations ≥ the Cut-off</title>
        <description>The cut-off for the assay was 15 EL.U/mL.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-Bordetella Pertussis (BPT) With Concentrations ≥ the Cut-off</title>
          <description>The cut-off for the assay was 15 EL.U/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-BPT, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-BPT, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations ≥ the Cut-off</title>
        <description>The cut-off for the assay was 0.1 milli-international units per milliliter (mIU/mL).</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-diphtheria (Anti-DT) and Anti-tetanus Toxoids (Anti-TT) Antibody Concentrations ≥ the Cut-off</title>
          <description>The cut-off for the assay was 0.1 milli-international units per milliliter (mIU/mL).</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-DT, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-DT, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TT, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-TT, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off</title>
        <description>The cut-off for the assay was 0.15 μg/mL.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration ≥ the Cut-off</title>
          <description>The cut-off for the assay was 0.15 μg/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PRP, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-PRP Antibody Concentration ≥ the Cut-off</title>
        <description>The cut-off for the assay was 1.0 μg/mL.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-PRP Antibody Concentration ≥ the Cut-off</title>
          <description>The cut-off for the assay was 1.0 μg/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all subjects for whom assay results were available for antibodies against at least one study vaccine antigen component for the blood sampling taken before the administration of the study booster dose (pre-booster blood sampling).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PRP, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off</title>
        <description>The cut-off for the assay was 10 mIU/mL.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations ≥ the Cut-off</title>
          <description>The cut-off for the assay was 10 mIU/mL.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HBs, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HBs, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Anti-polio Type 1, 2 and 3 (Anti-Polio 1, 2 and 3) Antibody Titers ≥ the Cut-off</title>
        <description>The cut-off for the assay was 8.</description>
        <time_frame>Prior to (Month 0) and one month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Anti-polio Type 1, 2 and 3 (Anti-Polio 1, 2 and 3) Antibody Titers ≥ the Cut-off</title>
          <description>The cut-off for the assay was 8.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Polio 1, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3, Month 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3, Month 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Vaccine Response to Anti-Bordetella Pertussis (BPT)</title>
        <description>Vaccine response for anti-BPT, defined as the appearance of antibodies in subjects seronegative at pre-vaccination, or at least 2-fold increase of pre-vaccination antibody concentrations in those who were initially seropositive at pre-vaccination.</description>
        <time_frame>One month after booster vaccination (Month 1)</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O2">
            <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
            <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
          </group>
          <group group_id="O3">
            <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
          </group>
          <group group_id="O4">
            <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
            <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Vaccine Response to Anti-Bordetella Pertussis (BPT)</title>
          <description>Vaccine response for anti-BPT, defined as the appearance of antibodies in subjects seronegative at pre-vaccination, or at least 2-fold increase of pre-vaccination antibody concentrations in those who were initially seropositive at pre-vaccination.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects for whom immunogenicity data were available. This included subjects for whom assay results were available for antibodies against at least one study vaccine antigen component after booster vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-BPT, S-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-BPT, S+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local and general symptoms during the 4-day and unsolicited AEs during the 31- day after booster vaccination; serious adverse events (SAEs): throughout the entire study period from Month 0 to Month 6</time_frame>
      <desc>The solicited local and general symptoms were only collected for those subjects who filled in their symptom sheets.</desc>
      <group_list>
        <group group_id="E1">
          <title>Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group</title>
          <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.</description>
        </group>
        <group group_id="E2">
          <title>Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group</title>
          <description>Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.</description>
        </group>
        <group group_id="E3">
          <title>Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
          <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.</description>
        </group>
        <group group_id="E4">
          <title>Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group</title>
          <description>Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix™ and Poliorix™ at 12-18 months of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hypoglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Enterocolitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Infestation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Internal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Hepatoblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="237" subjects_at_risk="280"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="276" subjects_at_risk="285"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="203" subjects_affected="203" subjects_at_risk="280"/>
                <counts group_id="E2" events="66" subjects_affected="66" subjects_at_risk="93"/>
                <counts group_id="E3" events="249" subjects_affected="248" subjects_at_risk="285"/>
                <counts group_id="E4" events="77" subjects_affected="77" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="138" subjects_affected="138" subjects_at_risk="280"/>
                <counts group_id="E2" events="51" subjects_affected="51" subjects_at_risk="93"/>
                <counts group_id="E3" events="219" subjects_affected="215" subjects_at_risk="285"/>
                <counts group_id="E4" events="65" subjects_affected="65" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="92" subjects_affected="92" subjects_at_risk="280"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="93"/>
                <counts group_id="E3" events="158" subjects_affected="158" subjects_at_risk="285"/>
                <counts group_id="E4" events="52" subjects_affected="52" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="15" subjects_affected="14" subjects_at_risk="285"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="285"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="285"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="97" subjects_affected="97" subjects_at_risk="280"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="93"/>
                <counts group_id="E3" events="184" subjects_affected="184" subjects_at_risk="285"/>
                <counts group_id="E4" events="57" subjects_affected="57" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="90" subjects_affected="90" subjects_at_risk="280"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="93"/>
                <counts group_id="E3" events="190" subjects_affected="190" subjects_at_risk="285"/>
                <counts group_id="E4" events="66" subjects_affected="66" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="173" subjects_affected="173" subjects_at_risk="280"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="93"/>
                <counts group_id="E3" events="244" subjects_affected="244" subjects_at_risk="285"/>
                <counts group_id="E4" events="79" subjects_affected="79" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="107" subjects_affected="107" subjects_at_risk="280"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="93"/>
                <counts group_id="E3" events="197" subjects_affected="197" subjects_at_risk="285"/>
                <counts group_id="E4" events="66" subjects_affected="66" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

